252 related articles for article (PubMed ID: 12014598)
1. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
Dwivedi S; Pavuluri M; Heidenreich J; Wright T
J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598
[No Abstract] [Full Text] [Related]
2. The first Japanese pediatric case of obsessive-compulsive disorder who responded to a selective serotonin re-uptake inhibitor.
Furusho J; Kubagawa T; Saitoh N; Matsuzaki K; Yamakawa H; Iikura Y
Pediatr Int; 2000 Aug; 42(4):451-2. PubMed ID: 10986886
[No Abstract] [Full Text] [Related]
3. Obsessive-compulsive disorder with non-24-hour sleep-wake syndrome.
Morinobu S; Yamashita H; Yamawaki S; Tanaka K; Ohkawa M
J Clin Psychiatry; 2002 Sep; 63(9):838-40. PubMed ID: 12363127
[No Abstract] [Full Text] [Related]
4. Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels.
Yoshimura R; Kaneko S; Shinkai K; Nakamura J
Psychiatry Clin Neurosci; 2006 Jun; 60(3):389-93. PubMed ID: 16732759
[TBL] [Abstract][Full Text] [Related]
5. Tiagabine augmentation to fluvoxamine-risperidone combination in the treatment of obsessive-compulsive disorder.
Oulis P; Masdrakis VG; Karapoulios E; Karakatsanis NA; Kouzoupis AV; Konstantakopoulos G; Soldatos CR
World J Biol Psychiatry; 2009; 10(4 Pt 3):953-5. PubMed ID: 19224410
[TBL] [Abstract][Full Text] [Related]
6. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology.
Agid O; Lerer B
J Clin Psychiatry; 1999 Jan; 60(1):55-6. PubMed ID: 10074882
[No Abstract] [Full Text] [Related]
7. Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination.
Pratheesh PJ; Praharaj SK; Srivastava A
Psychopharmacol Bull; 2011; 44(1):70-3. PubMed ID: 22506441
[TBL] [Abstract][Full Text] [Related]
8. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
McDougle CJ; Fleischmann RL; Epperson CN; Wasylink S; Leckman JF; Price LH
J Clin Psychiatry; 1995 Nov; 56(11):526-8. PubMed ID: 7592506
[TBL] [Abstract][Full Text] [Related]
9. A case of social phobia with obsessive-compulsive symptoms improved by paroxetine in combination with risperidone.
Yamauchi K; Ohta K; Taniguchi T; Ohmori T
Gen Hosp Psychiatry; 2004; 26(3):242-3. PubMed ID: 15121355
[No Abstract] [Full Text] [Related]
10. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.
Shalbafan M; Malekpour F; Tadayon Najafabadi B; Ghamari K; Dastgheib SA; Mowla A; Shirazi E; Eftekhar Ardebili M; Ghazizadeh-Hashemi M; Akhondzadeh S
J Psychopharmacol; 2019 Nov; 33(11):1407-1414. PubMed ID: 31575326
[TBL] [Abstract][Full Text] [Related]
11. Comparable dopamine 2 receptor occupancy.
de Haan L; van Amelsvoort T
Am J Psychiatry; 2002 Dec; 159(12):2118; author reply 2118-9. PubMed ID: 12450982
[No Abstract] [Full Text] [Related]
12. The use of sumatriptan in the treatment of obsessive-compulsive disorder in an adolescent.
Pathak S; Cottingham EM; McConville BJ
J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S93-4. PubMed ID: 12880505
[No Abstract] [Full Text] [Related]
13. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions.
Goodman WK; Ward H; Kablinger A; Murphy T
J Clin Psychiatry; 1997; 58 Suppl 5():32-49. PubMed ID: 9184625
[TBL] [Abstract][Full Text] [Related]
14. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
[TBL] [Abstract][Full Text] [Related]
15. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study.
Emamzadehfard S; Kamaloo A; Paydary K; Ahmadipour A; Zeinoddini A; Ghaleiha A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
Psychiatry Clin Neurosci; 2016 Aug; 70(8):332-41. PubMed ID: 27106362
[TBL] [Abstract][Full Text] [Related]
16. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder.
Fitzgerald KD; Stewart CM; Tawile V; Rosenberg DR
J Child Adolesc Psychopharmacol; 1999; 9(2):115-23. PubMed ID: 10461822
[TBL] [Abstract][Full Text] [Related]
17. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
18. Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.
Andrade C
J Clin Psychiatry; 2012 Nov; 73(11):e1362-4. PubMed ID: 23218164
[No Abstract] [Full Text] [Related]
19. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
[TBL] [Abstract][Full Text] [Related]
20. Late onset OCD.
Bhattacharyya S; Khanna S
Aust N Z J Psychiatry; 2004 Jun; 38(6):477-8. PubMed ID: 15209842
[No Abstract] [Full Text] [Related]
[Next] [New Search]
